In last trading session, CymaBay Therapeutics, Inc. (NASDAQ:CBAY) saw 1,815,705 shares changing hands with its beta currently measuring 1.64. Company’s recent per share price level of $6.64 trading at $0.15 or 2.31% at ring of the bell on the day assigns it a market valuation of $457.41 Million. That closing price of CBAY’s stock is at a discount of -6.78% from its 52-week high price of $7.09 and is indicating a premium of 81.78% from its 52-week low price of $1.21. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.54 Million shares which gives us an average trading volume of 3.63 Million if we extend that period to 3-months.

For CymaBay Therapeutics, Inc. (CBAY), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.5. Splitting up the data highlights that, out of 10 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 10 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.16 in the current quarter.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) trade information

Upright in the green today for gaining 2.31%, in the last five days CBAY remained trading in the green while hitting it’s week-highest on Wednesday, Sep 16 when the stock touched $6.89-3 price level, adding 3.63% to its value on the day. CymaBay Therapeutics, Inc.’s shares saw a change of 238.78% in year-to-date performance and have moved 11.6% in past 5-day. CymaBay Therapeutics, Inc. (NASDAQ:CBAY) showed a performance of 13.12% in past 30-days. Number of shares sold short was 6.35 Million shares which calculate 1.75 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $12.8 to the stock, which implies a rise of 92.77% to its current value. Analysts have been projecting $8 as a low price target for the stock while placing it at a high target of $20. It follows that stock’s current price would jump +201.2% in reaching the projected high whereas dropping to the targeted low would mean a loss of 20.48% for stock’s current value.

CymaBay Therapeutics, Inc. (CBAY) estimates and forecasts

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 10.4% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -22.2% while estimates for its earnings growth in next 5 years are of 0%

CymaBay Therapeutics, Inc. (NASDAQ:CBAY)’s Major holders

Insiders are in possession of 0.62% of company’s total shares while institution are holding 88.01% percent of that, with stock having share float percentage of 88.55%. Investors also watch the number of corporate investors in a company very closely, which is 154 institutions for CymaBay Therapeutics, Inc. that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at CBAY for having 5.62 Million shares of worth $19.6 Million. And as of June 29, 2020, it was holding 8.15% of the company’s outstanding shares.

The second largest institutional holder is Avoro Capital Advisors LLC, which was holding about 5.25 Million shares on June 29, 2020. The number of shares represents firm’s hold over 7.62% of outstanding shares, having a total worth of $18.32 Million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of June 29, 2020, the former fund manager was holding 1953114 shares of worth $6.82 Million or 2.84% of the total outstanding shares. The later fund manager was in possession of 1.46 Million shares on June 29, 2020, making its stake of worth around $5.11 Million in the company or a holder of 2.13% of company’s stock.